Tesamorelin, a human growth hormone releasing factor analogue

Bibliography

• Lin-Su K, Wajnrajch MP. Growth Hormone Releasing Hormone (GHRH) and the GHRH Receptor. Rev Endocr Metab Disord 2002;3(4):313-23
   PubMedGoogle Scholar
• Giustina A, Veldhuis JD. Pathophysiology of the neuroregulation of growth hormone secretion in experimental animals and the human. Endocr Rev 1998;19:717-97
   PubMed Web of Science ®Google Scholar
• Kojima M, Hosoda H, Date Y, et al. Ghrelin is a growth-hormone-releasing acylated peptide from stomach. Nature 1999;402:656-60
   PubMed Web of Science ®Google Scholar
• Takaya K, Ariyasu H, Kanamoto N, et al. Ghrelin strongly stimulates growth hormone release in humans. J Clin Endocrinol Metab 2000;85:4908-11
   PubMed Web of Science ®Google Scholar
• Zadik Z, Chalew SA, McCarter RJ Jr, et al. The influence of age on the 24-hour integrated concentration of growth hormone in normal individuals. J Clin Endocrinol Metab 1985;60:513-6
   PubMed Web of Science ®Google Scholar
• Veldhuis JD, Bowers CY. Human GH pulsatility: an ensemble property regulated by age and gender. J Endocrinol Invest 2003;26:799-813
   PubMed Web of Science ®Google Scholar
• van den Berg G, Veldhuis JD, Frolich M, et al. An amplitude-specific divergence in the pulsatile mode of GH secretion underlies the gender difference in mean GH concentrations in men and premenopausal women. J Clin Endocrinol Metab 1996;81:2460-6
   PubMed Web of Science ®Google Scholar
• Ho KKY, Evans WS, Blizzard RM, et al. Effects of sex and age on the 24-hour profile of growth hormone secretion in man: importance of endogenous estradiol concentrations. J Clin Endocrinol Metab 1987;64:51-8
   PubMed Web of Science ®Google Scholar
• Coiro V, Volpi R, Bertoni P, et al. Effect of potentiation of cholinergic tone by pyridostigmine on the GH response to GHRH in elderly men. Gerontology 2002;38:217-22
   Google Scholar
• Veldhuis JD, Iranmanesh A. Physiological regulation of the human growth hormone (GH)-insulin-like growth factor type I (IGF-I) axis: predominant impact of age, obesity, gonadal function, and sleep. Sleep 1996;19:S221-4
   PubMed Web of Science ®Google Scholar
• Landin-Wilhelmsen K, Wilhelmsen L, Lappas G, et al. Serum insulin-like growth factor I in a random population of men and women: Relation to age, sex, smoking habits, coffee consumption and physical activity, blood pressure and concentrations of plasma lipids, fibrinogen, parathyroid hormone and osteocalcin. Clin Endocrinol (Oxf) 1996;41:2209-15
   Google Scholar
• Savine R, Sonksen P. Growth hormone–hormone replacement for the somatopause? Horm Res 2000;53(Suppl 3):37-41
   PubMed Web of Science ®Google Scholar
• Young A. Muscle function in old age. New Iss Neurosci 1998;I:141-56
   Google Scholar
• Skelton DA, Grieg CA, Davies JM, et al. Strength, power and related functional ability of healthy people aged 60 – 89 years. Age Ageing 1994;23:371-7
   PubMed Web of Science ®Google Scholar
• Bohannon RW. Comfortable and maximum walking speed of adults aged 20 – 79 years: reference values and determinants. Age Ageing 1997;26:15-9
   PubMed Web of Science ®Google Scholar
• Ayuk J, Sheppard MC. Growth hormone and its disorders. Postgrad Med J 2006;82(963):24-30
   PubMed Web of Science ®Google Scholar
• Ottosson M, Vikman-Adolfsson K, Enerback S, et al. Growth hormone inhibits lipoprotein lipase activity in human adipose tissue. J Clin Endocrinol Metab 1995;80(3):936-41
   PubMed Web of Science ®Google Scholar
• Schwarz JM, Mulligan K, Lee J, et al. Effects of recombinant human growth hormone on hepatic lipid and carbohydrate metabolism in HIV-infected patients with fat accumulation. J Clin Endocrinol Metab 2002;87(2):942
   PubMed Web of Science ®Google Scholar
• Brandou F, Aloulou I, Razimbaud A, et al. Lower ability to oxidize lipids in adult patients with growth hormone (GH) deficiency: reversal under GH treatment. Clin Endocrinol (Oxf) 2006;65(4):423-8
   PubMed Web of Science ®Google Scholar
• Rosen T, Bengtsson BA. Premature mortality due to cardiovascular disease in hypopituitarism. Lancet 1990;336:285-8
   PubMed Web of Science ®Google Scholar
• Bates AS, Van't Hoff W, Jones PJ, Clayton RN. The effect of hypopituitarism on life expectancy. J Clin Endocrinol Metab 1996;81:1169-72
   PubMed Web of Science ®Google Scholar
• Bulow B, Hagmart L, Mikoczy Z, et al. Increased cerebrovascular mortality in patients with hypopituitarism. Clin Endocrinol 1997;46:75-81
   PubMed Web of Science ®Google Scholar
• Tomlinson JW, Holden N, Hills RK, et al. Association between premature mortality and hypopituitarism. West Midlands Prospective Hypopituitary Study Group. Lancet 2001;357:425-31
   PubMed Web of Science ®Google Scholar
• Van der Lely AJ. Justified and unjustified use of growth hormone. Postgrad Med J 2004;80(948):577-80
   PubMed Web of Science ®Google Scholar
• Khorram O. Use of growth hormone and growth hormone secretagogues in aging: help or harm. Clin Obstet Gynecol 2001;44(4):893-901
   PubMed Web of Science ®Google Scholar
• Carr A, Samaras K, Thoridottir A, et al. Diagnosis, prediction, and natural course of HIV-1 protease-inhibitor-associated lipodystrophy, hyperlipidaemia, and diabetes mellitus: a cohort study. Lancet 1999;53:2093-9
   Google Scholar
• Gervasoni C, Ridolfo AL, Trifiro G, et al. Redistribution of body fat in HIV-infected women undergoing combined antiretroviral therapy. AIDS 1999;13:465-71
   PubMed Web of Science ®Google Scholar
• Grinspoon S, Carr A. Cardiovascular risk and body-fat abnormalities in HIV-infected adults. N Engl J Med 2005;352(1):48-62
   PubMed Web of Science ®Google Scholar
• Grinspoon S, Gelato M. The rational use of growth hormone in HIV-infected patients. J Clin Endocrinol Metab 2001;86:3478-9
   PubMed Web of Science ®Google Scholar
• D'Amico S, Shi J, Sekhar RV, et al. Physiologic growth hormone replacement improves fasting lipid kinetics in patients with HIV lipodystrophy syndrome. Am J Clin Nutr 2006;84(1):204-11
   PubMed Web of Science ®Google Scholar
• Lo J, You SM, Canavan B, et al. Low-dose physiological growth hormone in patients with HIV and abdominal fat accumulation: a randomized controlled trial. JAMA 2008;300(5):509-19
   PubMed Web of Science ®Google Scholar
• Chappel S. Can GHRH or GH secretagogues re-initiate pituitary GH pulsatility? Clin Endocrinol 1999;50(5):547-56
   PubMed Web of Science ®Google Scholar
• Corpas E, Harman SM, Pineyro MA, et al. Continuous subcutaneous infusions of growth hormona (GH) releasing hormone 1-44 for 14 days incrase GH and insulin-like growth factor-I levels in old men. J Clin Endocrinol Metab 1993;76(1):1134-8
   Google Scholar
• Root AW, Root MJ. Clinical pharmacology of human growth hormone and its secretagogues. Curr Drug Targets Immune Endocr Metabol Disord 2002;2(1):27-52
   PubMedGoogle Scholar
• Forhman LA, Downs TR, Williams TC, et al. Rapid enzymatic degradation of growth hormone-releasing hormone by plasma in vitro and in vivo to a biologically inactive product cleaved at the NH2 terminus. Am J Clin Invest 1986;78(4):906-13
   PubMed Web of Science ®Google Scholar
• Abribat T, Chapdelaine A, Gravel D, et al. TH 9507, a new growth hormone-releasing factor (GFR) analogue, is a powerful insulin-like growth factor-1(IGF-1) inducer in 50-60 year old healthy subjects: A 7-day randomized multidose study. Endocr Soc 2001;83:292
   Google Scholar
• Falutz J, Allas S, Kotler D, Thompson M. A placebo-controlled, dose-ranging study of a growth hormone releasing factor in HIV-infected patients with abdominal fat accumulation. AIDS 2005;19(12):1279-87
   PubMed Web of Science ®Google Scholar
• Schols AMWJ, Maltais F, O'Donnell DE, et al. Anabolic effects and safety assessments of TH9507, a growth hormone releasing factor (GRF) analog, in patients with COPD-associated wasting. Eur Respir J 2004;24(48):P1888
   Google Scholar
• Tomlinson B. Drug evaluation: tesamorelin, a synthetic human growth hormone releasing factor. Curr Opin Investig Drugs 2006;7(10):936-45
   PubMed Web of Science ®Google Scholar
• Thorner M, Rochiccioli P, Colle M, et al. Once daily subcutaneous growth hormone-releasing hormone therapy accelerates growth in growth hormone-deficient children during the first year of therapy. Geref International Study Group. J Clin Endocrinol Metab 1996;81(3):1189-96
   PubMed Web of Science ®Google Scholar
• Chen RG, Shen YN, Yei J, et al. A comparative study of growth hormone (GH) and GH-releasing hormone (1-29)-NH2 for stimulation of growth in children with GH deficiency. Acta Paediatr Suppl 1993;388:32-5
   PubMedGoogle Scholar
• Neyzi O, Yordam N, Ocal G, et al. Growth response to growth hormone-releasing hormone (1-29)-NH2 compared with growth hormone. Acta Paediatr Suppl 1993;388:16-21
   PubMedGoogle Scholar
• Broglio F, Benso A, Gottero C, et al. Endocrine activities of alexamorelin (Ala-His-D-2-methyl-Trp-Ala-Trp-D-Phe-Lys-NH2), a synthetic GH secretagogue, in humans. Eur J Endocrinol 2000;143(3):419-25
   PubMed Web of Science ®Google Scholar
• Bisi G, Podio V, Valetto MR, et al. Acute cardiovascular and hormonal effects of GH and hexarelin, a synthetic GH-releasing peptide, in humans. J Endocrinol Invest 1999;22(4):266-72
   PubMed Web of Science ®Google Scholar
• LAB International Inc. Company. Available from: http://www.labinc.ca/products.html [Accessed 30 May 2008]
   Google Scholar
• Bohlen P, Esch F, Brazeau B, et al. Isolation and characterization of the porcine hypothalamic growth hormone releasing factor. Biochem Biophys Res Commun 1983;116:726-34
   PubMed Web of Science ®Google Scholar
• Bohlen P, Wehrenberg WP, Esch F, et al. Rat hypothalamic growth hormone-releasing factor: isolation, sequence analysis and total synthesis. Biochem Biohys Res Commun 1984;125:1005-12
   PubMed Web of Science ®Google Scholar
• Brazeau P, Bohlen P, Esch F, et al. Growth hormone-releasing factor from ovine and caprine hypothalamus: isolation, sequence analysis and total synthesis. Biochem Biophys Res Commun 1984;125:606-14
   PubMed Web of Science ®Google Scholar
• Campbell RM, Bongers J, Felix AM. Rational design, synthesis, and biological evaluation of novel growth hormone-releasing factor analogues. Biopolymers 1995;37:67-88
   PubMed Web of Science ®Google Scholar
• Dubreuil P, Desevaux C. Growth hormone-releasing factor: structural modification and protection for more potent analogues. Comb Chem High Throughput Screen 2006;9:171-4
   PubMed Web of Science ®Google Scholar
• Larocque A, Vaillancourt C, Abribat T, et al. Anchoring rigid hydrophobic chains to stabilize growth hormone-releasing factor [abstract 382]. 17th American Peptide Symposium, San Diego, USA, 9 – 14 June 2001, Abstract book. p. 365. Proc Am Pept Symp 2001;17
   Google Scholar
• Ferdinandi ES, Brazeau P, High K, et al. Non-clinical pharmacology and safety evaluation of TH9507, a human growth hormone-releasing factor analogue. Basic Clin Pharmacol Toxicol 2007;100(1):49-58
   PubMed Web of Science ®Google Scholar
• High KA, Gritsas A, Tsikos T, et al. Assessment of ex vivo DPP IV proteolytic cleavage of TH9507 in rat, dog and human plasma by LC/MS [abstract]. Proc Asms Conf Mass Spect Allied Topics San Antonio, TX, USA; 2005
   Google Scholar
• Jansen M, Darby I, Abribat T, et al. Pulmonary delivery of TH9507, a growth hormone releasing factor analogue, in the dog. Int J Pharm 2004;276(1-2):75-81
   PubMed Web of Science ®Google Scholar
• Allas S, Lussier B, Chapdelaine A, et al. Endocrine and metabolic effects of TH9507, a growth hormone-releasing factor (GRF) analogue, in elderly male and female subjects [abstract 382]. ENDO 2004, 86th Annual Meeting of The Endocrine Society, New Orleans, USA, 16 – 19 June 2004. Endocr Soc 2004;86
   Google Scholar
• Alexandre B, Allas S, De Villers A, et al. Effects of gender on the insulin-like growth factor-1 response to repeated administration of TH9507, a long acting growth-hormone releasing factor analogue [abstract 85]. 85th Annual Meeting of the Endocrine Society, Philadelphia, USA, 18 June 2003. Endocr Soc 2003;85
   Google Scholar
• Maltais F, O'Donnell DE, Schols AMWJ, et al. Effect of TH9507, a growth hormone releasing factor (GFR) analog, on functional performance in patients with COPD [Abstract]. Eur Respir J 2004;24(48):P1603
   Web of Science ®Google Scholar
• Maltais F, O'Donnell DE, Schols AMWJ, et al. Effect of TH9507, a growth hormone-releasing factor (GFR) analogue, on health-related quality of life and respiratory muscle function in patients with COPD-associated wasting [abstract 4342]. Proc Am Thorac Soc 2005
   Google Scholar
• Falutz J, Allas S, Blot K, et al. Metabolic effects of growth hormone-releasing factor in patients with HIV. N Engl J Med 2007;357(23):2359-70
   PubMed Web of Science ®Google Scholar
• Ferdinandi ES, Brazeau P, High K, et al. Non-clinical pharmacology and safety evaluation of TH9507, a human growth hormone-releasing factor analogue. Basic Clin Pharmacol Toxicol 2007;100(1):49-58
   PubMed Web of Science ®Google Scholar